Senators Alsobrooks and Wyden press HHS on prediction markets tied to drug trials
Sens. Angela Alsobrooks and Ron Wyden asked the Department of Health and Human Services what steps it has taken to mitigate risks from prediction markets tied to clinical trials and drug approvals. The Democratic lawmakers raised the issue in a statement Wednesday. Their inquiry reflects congressional concern that event contracts on medical outcomes could create perverse incentives or undermine the integrity of the drug development process. The specific contracts and platforms involved were not identified.
The inquiry opens a third federal front against prediction markets alongside CFTC swap-rule proposals and Justice Department ethics complaints. Health policy carries bipartisan moral weight that financial regulation lacks; any HHS finding that trial betting threatens patient safety becomes evidence Congress can cite for a statutory ban.
Operators like Kalshi and Polymarket now face scrutiny from banking, oversight, and health committees simultaneously. Each new federal investigation normalizes state gambling suits and makes preemption harder to defend. The pharmaceutical lobby, vastly larger than the gaming industry, could join Warren and Khanna in seeking prohibition. For platforms, the risk is that a health-framed ban overrides CFTC registration entirely.
Joins a coordinated Democratic oversight push that already includes Warren's Banking Committee subpoena threats, Khanna's ban demand, and the felony summons facing Kalshi's co-founders in Utah, widening the attack from financial regulation into health and criminal spheres.